Geneva, March 20 -- International Clinical Trials Registry received information related to the study (NCT07458659) titled 'Clinical Study of BCMA-Targeted CAR T-Cell Injection in the Treatment of Patients With Relapsed/Refractory Multiple Myeloma' on Feb. 26.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Chulalongkorn University
Condition:
Relapsed/Refractory Multiple Myeloma (MM)
Intervention:
Biological: Chimeric Antigen Receptor T Cells (CAR-T)
Recruitment Status: Not recruiting
Phase: Early Phase 1
Date of First Enrollment: June 1, 2026
Target Sample Size: 3
Countries of Recruitment:
Thaila...